Detalhe da pesquisa
1.
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
J Thromb Thrombolysis;
41(3): 374-83, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26573179
2.
Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med;
360(4): 354-62, 2009 Jan 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19106084
3.
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Br J Clin Pharmacol;
73(1): 93-105, 2012 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21689142
4.
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Lancet;
376(9749): 1312-9, 2010 Oct 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20801494
5.
Clopidogrel pharmacogenetics: metabolism and drug interactions.
Drug Metabol Drug Interact;
26(2): 45-51, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21819266
6.
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Circulation;
119(19): 2553-60, 2009 May 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19414633
7.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
Lancet;
374(9694): 989-997, 2009 Sep 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19726078
8.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Eur Heart J;
30(14): 1744-52, 2009 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19429918
9.
Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?
Fundam Clin Pharmacol;
26(1): 19-26, 2012 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21880067
10.
TRITON and beyond: new insights into the profile of prasugrel.
Cardiovasc Ther;
30(4): e174-82, 2012 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21883999
11.
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
Pharmacogenomics;
11(12): 1637-47, 2010 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21142906
12.
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Neuropsychopharmacology;
34(9): 2135-42, 2009 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19387424